Solid state forms of HDAC inhibitors
The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DENG XIAOHU MAI WANPING MCCRAE ROBERT C NAGISSON BARTI, BILIANA |
| description | The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide may be used in the preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders, and inflammation.
本公开涉及N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1及其制备方法。N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1可用于制备用于治疗癌症、免疫障碍和炎症的药物组合物和剂型。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN116648449A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN116648449A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN116648449A3</originalsourceid><addsrcrecordid>eNrjZFAJzs_JTFEoLkksSVVIyy_KLVbIT1PwcHF0VsjMy8hMyizJLyrmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxzn6GhmZmJhYmJpaOxsSoAQDDtCYk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Solid state forms of HDAC inhibitors</title><source>esp@cenet</source><creator>DENG XIAOHU ; MAI WANPING ; MCCRAE ROBERT C ; NAGISSON BARTI, BILIANA</creator><creatorcontrib>DENG XIAOHU ; MAI WANPING ; MCCRAE ROBERT C ; NAGISSON BARTI, BILIANA</creatorcontrib><description>The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide may be used in the preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders, and inflammation.
本公开涉及N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1及其制备方法。N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1可用于制备用于治疗癌症、免疫障碍和炎症的药物组合物和剂型。</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230825&DB=EPODOC&CC=CN&NR=116648449A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230825&DB=EPODOC&CC=CN&NR=116648449A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DENG XIAOHU</creatorcontrib><creatorcontrib>MAI WANPING</creatorcontrib><creatorcontrib>MCCRAE ROBERT C</creatorcontrib><creatorcontrib>NAGISSON BARTI, BILIANA</creatorcontrib><title>Solid state forms of HDAC inhibitors</title><description>The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide may be used in the preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders, and inflammation.
本公开涉及N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1及其制备方法。N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1可用于制备用于治疗癌症、免疫障碍和炎症的药物组合物和剂型。</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFAJzs_JTFEoLkksSVVIyy_KLVbIT1PwcHF0VsjMy8hMyizJLyrmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxzn6GhmZmJhYmJpaOxsSoAQDDtCYk</recordid><startdate>20230825</startdate><enddate>20230825</enddate><creator>DENG XIAOHU</creator><creator>MAI WANPING</creator><creator>MCCRAE ROBERT C</creator><creator>NAGISSON BARTI, BILIANA</creator><scope>EVB</scope></search><sort><creationdate>20230825</creationdate><title>Solid state forms of HDAC inhibitors</title><author>DENG XIAOHU ; MAI WANPING ; MCCRAE ROBERT C ; NAGISSON BARTI, BILIANA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN116648449A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>DENG XIAOHU</creatorcontrib><creatorcontrib>MAI WANPING</creatorcontrib><creatorcontrib>MCCRAE ROBERT C</creatorcontrib><creatorcontrib>NAGISSON BARTI, BILIANA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DENG XIAOHU</au><au>MAI WANPING</au><au>MCCRAE ROBERT C</au><au>NAGISSON BARTI, BILIANA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Solid state forms of HDAC inhibitors</title><date>2023-08-25</date><risdate>2023</risdate><abstract>The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide may be used in the preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders, and inflammation.
本公开涉及N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1及其制备方法。N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1可用于制备用于治疗癌症、免疫障碍和炎症的药物组合物和剂型。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN116648449A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| title | Solid state forms of HDAC inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A24%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DENG%20XIAOHU&rft.date=2023-08-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN116648449A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |